CDK4 and breast cancer: However, recent studies indicated that exposure of RB1-intact breast cancer cells to a CDK4/6 inhibitor continuously prior to exposure to cytotoxic agents, such as doxorubicin and carboplatin, significantly reduced their cytotoxicity [20, 21].